Skip to main content
Premium Trial:

Request an Annual Quote

Dennis Shields, Kevin Sayer

Premium
Dennis Shields was named the first member of Alfa Wassermann Proteomic Technologies’ scientific board last week. Shields is a professor of development and molecular biology, and anatomy and structural biology at the Albert Einstein College of Medicine. Shields received his PhD at the National Institute for Medical Research in London.
 

 
Eksigent said this week Kevin Sayer has joined its board. Sayer is a consultant to the drug and biotech industries with expertise in medical devices and finance, Eksigent said in a statement. Sayer has held positions at MiniMed/Medtronic MiniMed, Ernst & Young, and Specialty Labs.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.